67.52
1.69%
+1.12
Handel nachbörslich:
67.52
Schlusskurs vom Vortag:
$66.40
Offen:
$66.4
24-Stunden-Volumen:
555.03K
Marktkapitalisierung:
$7.34B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-402.27M
KGV:
-17.42
EPS:
-3.876
Netto-Cashflow:
$-364.67M
1W Leistung:
+11.51%
1M Leistung:
+5.52%
6M Leistung:
+34.37%
1J Leistung:
+31.36%
Vaxcyte Inc Stock (PCVX) Company Profile
Firmenname
Vaxcyte Inc
Sektor
Branche
Telefon
650 837 0111
Adresse
353 Hatch Drive, Foster City, CA
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-12-07 | Eingeleitet | Mizuho | Buy |
2023-04-18 | Eingeleitet | TD Cowen | Outperform |
2023-01-03 | Bestätigt | Needham | Buy |
2022-12-15 | Eingeleitet | Guggenheim | Buy |
2022-11-17 | Eingeleitet | BTIG Research | Buy |
2021-12-29 | Fortgesetzt | Jefferies | Buy |
2021-06-24 | Fortgesetzt | Jefferies | Buy |
2020-07-07 | Eingeleitet | BofA Securities | Buy |
2020-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
2020-07-07 | Eingeleitet | Needham | Buy |
Alle ansehen
Vaxcyte Inc Aktie (PCVX) Neueste Nachrichten
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
Benzinga
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
GlobeNewswire Inc.
Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Should Know
Zacks Investment Research
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire Inc.
Finanzdaten der Vaxcyte Inc-Aktie (PCVX)
Vaxcyte Inc (PCVX) Nettogewinn 2024
PCVX betrug am 2023-12-31 der Nettogewinn der letzten 12 Monate -402.27 Millionen US-Dollar, was einem Rückgang von -80.00% im Vergleich zum Vorjahr entspricht.
Vaxcyte Inc (PCVX) Free Cashflow 2024
PCVX verzeichnete einen Free Cashflow der letzten 12 Monate von -364.67 Millionen US-Dollar für das Quartal bis zum 2023-12-31, was einem Rückgang von -106.67% im Vergleich zum Vorjahr entspricht.
Vaxcyte Inc (PCVX) Gewinn je Aktie 2024
Der Gewinn je Aktie (EPS) von PCVX für die letzten 12 Monate betrug -4.7519 US-Dollar für das Quartal, das am 2023-12-31 endete, was einem Rückgang von -38.54% im Vergleich zum Vorjahr entspricht.
Vaxcyte Inc-Aktie (PCVX) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
May 01 '24 |
Option Exercise |
21.41 |
1,667 |
35,690 |
32,264 |
Wassil Jim | CHIEF OPERATING OFFICER |
May 01 '24 |
Sale |
61.65 |
3,000 |
184,942 |
215,462 |
PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
May 01 '24 |
Sale |
61.70 |
2,616 |
161,419 |
146,054 |
Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
May 01 '24 |
Sale |
61.74 |
1,667 |
102,921 |
30,597 |
PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Apr 23 '24 |
Option Exercise |
1.79 |
15,000 |
26,850 |
492,847 |
PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Apr 23 '24 |
Sale |
61.92 |
15,000 |
928,845 |
477,847 |
GUGGENHIME ANDREW | PRESIDENT AND CFO |
Apr 18 '24 |
Option Exercise |
5.35 |
8,000 |
42,800 |
103,679 |
GUGGENHIME ANDREW | PRESIDENT AND CFO |
Apr 18 '24 |
Sale |
61.27 |
8,000 |
490,199 |
95,679 |
Wassil Jim | CHIEF OPERATING OFFICER |
Apr 17 '24 |
Option Exercise |
5.35 |
3,551 |
18,998 |
221,840 |
Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Apr 01 '24 |
Option Exercise |
21.41 |
1,667 |
35,690 |
32,264 |
Kapitalisierung:
|
Volumen (24h):